Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian
stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the
importance in lieu of its oral availability, cheap, no cumbersome side effects and no definitive newer fetal side effects. After the
LOTUS 1 trial with a multicenter double placebo, double dummy design it has proved an equal efficacy if not superiority of oral D,
over micronized vaginal progesterone and it seems D might soon become the standard of care for LPS in conventional IVF cycles
besides its routine indication for recurrent abortions.